Considering the negative effect of anti‐CD47 mAb on host immune cells, the augmentation of macrophage phagocytic activity by anti‐SIRPα mAb may constitute an effective treatment for human gastrointestinal tumors. This evidence concerns the gene SIRPA and digestive system neoplasm.